Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections.

ABSTRACT: The efficacy, safety, and population pharmacokinetics of a single 1,500 mg dose of dalbavancin as a sequencing treatment for Gram-positive chronic prosthetic joint infections (CPJIs) have not been described. We present an observational, retrospective study conducted in two Spanish hospitals including patients with CPJI caused by Gram-positive bacteria susceptible to dalbavancin managed with two-stage exchange, antibiotic-loaded spacers, and a single 1,500 mg dose of dalbavancin. Follow-up visits included measurement of dalbavancin plasma concentrations. Negative intraoperative cultures at second-stage surgery defined microbiological cure. Population pharmacokinetics and Monte Carlo dosing simulations were used to evaluate whether this dose provided a therapeutic antibiotic exposure defined

SUBMITTER: Benavent E 

PROVIDER: S-EPMC12691635 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature